Research programme: JAK inhibitors - Celon PharmaAlternative Names: CPL 407 22; CPL 407 405; CPL-407-105
Latest Information Update: 18 Dec 2016
At a glance
- Originator Celon Pharma
- Class Small molecules
- Mechanism of Action Janus kinase-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia; Asthma; Myeloproliferative disorders